Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection.
Stem cell therapy for Long COVID is an investigational regenerative approach that uses living cells — such as mesenchymal stem cells and exosomes — to target the disease process. MSC and exosome protocols target the persistent inflammation and immune dysregulation behind long-COVID fatigue and brain-fog, as supportive care. It is not an approved cure for Long COVID: results come from early-phase clinical trials and clinic case series, not large randomised studies, and the realistic goal is slowed progression or symptom improvement rather than reversal.
Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection. Proposed mechanisms include persistent viral fragments in reservoir tissues, endothelial activation with microclot formation, dysregulated immune memory (skewed Th1/Th17 responses, reduced regulatory T cells), and mitochondrial dysfunction. Placental mesenchymal stem cells and exosomes address these pathways through endothelial repair, anti-inflammatory cytokine secretion, and metabolic rescue of dysfunctional immune cells. Eleven registered clinical trials and two actively recruiting protocols evaluate MSC and exosome infusions in long-COVID cohorts, predominantly focusing on severe functional impairment or cardiopulmonary involvement.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €2,700–€23,000 (placidway.com) |
| 研究的主要细胞类型 | MSCs from Amniotic Membrane, Exosomes |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 11 · 2 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published phase I safety data and small phase II trials (n=20–80 per arm) document symptomatic improvement in fatigue severity, exercise tolerance, and cognitive clarity in 40–55% of infused participants over 8–12 weeks. Objective markers—circulating microclot burden, endothelial dysfunction indices, IL-6 levels—show modest reduction in responder subgroups. One multicentre registry reports durable functional improvement (60-metre walk distance, sustained exertion capacity) persisting at 6 months in 45% of treated cohorts. Blinded controlled efficacy trials remain pending.
Depending on assessment, a Long COVID protocol may draw on:
Long-COVID MSC protocols in Sofia range €4,500–7,000 for treatment courses comprising 2–3 intravenous infusions over 6–12 weeks, alongside immunological and cardiopulmonary baseline assessment, post-treatment follow-up imaging (chest CT, echocardiography), and exercise tolerance testing. Specialised post-COVID clinics may charge facility and monitoring fees in addition to cell-preparation costs. International travel for treatment adds significantly to overall expense.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Long COVID cost-by-country breakdown, or compare the best countries for Long COVID →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Long COVID.
完整长期COVID常见问题 → · 长期COVID成本分解 →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Last reviewed 2026-07-23; see our editorial standards. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估